Novartis agreed to acquire Pikavation Therapeutics (a Synnovation subsidiary) for $2 billion upfront and up to $1 billion in milestones to secure SNV4818, a pan‑mutant‑selective PI3Kα inhibitor in Phase I/II testing for HR+/HER2‑ metastatic breast cancer and other solid tumors. Novartis positioned the buy as a precision‑medicine play intended to spare wild‑type PI3Kα and improve tolerability in combinations with endocrine and CDK4/6 inhibitors. Synnovation will retain other assets while Novartis gains global development and commercialization control for SNV4818. Company statements and trial identifiers (NCT06736704) indicate ongoing dose‑escalation and combination arms; Novartis said the chemistry offers stronger mutation selectivity seen in preclinical models. The acquisition adds to Novartis’s oncology push and reflects big‑pharma appetite to buy specialized small‑molecule programs with clear positioning for difficult‑to‑tolerate pathways. Observers will track tolerability and combination data and whether mutant selectivity translates to meaningful clinical differentiation.